1. Home
  2. JAZZ vs RNR Comparison

JAZZ vs RNR Comparison

Compare JAZZ & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

N/A

Current Price

$229.20

Market Cap

16.1B

Sector

Health Care

ML Signal

N/A

Logo RenaissanceRe Holdings Ltd.

RNR

RenaissanceRe Holdings Ltd.

N/A

Current Price

$345.35

Market Cap

14.6B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
JAZZ
RNR
Founded
2003
1993
Country
Ireland
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
16.1B
14.6B
IPO Year
2007
1996

Fundamental Metrics

Financial Performance
Metric
JAZZ
RNR
Price
$229.20
$345.35
Analyst Decision
Buy
Hold
Analyst Count
22
18
Target Price
$297.50
★ $356.75
AVG Volume (30 Days)
★ 715.5K
439.7K
Earning Date
11-02-2026
10-27-2026
Dividend Yield
N/A
★ 0.48%
EPS Growth
N/A
★ 59.13
EPS
0.04
★ 6.57
Revenue
$1,618,693,000.00
★ $12,848,074,000.00
Revenue This Year
$12.68
N/A
Revenue Next Year
$5.34
N/A
P/E Ratio
$5,907.78
★ $52.33
Revenue Growth
N/A
★ 9.86
52 Week Low
$156.95
$251.60
52 Week High
$266.38
$363.84

Technical Indicators

Market Signals
Indicator
JAZZ
RNR
Relative Strength Index (RSI) 48.42 47.88
Support Level $222.49 $316.64
Resistance Level $244.93 $363.18
Average True Range (ATR) 8.63 7.47
MACD 0.33 -1.47
Stochastic Oscillator 36.41 26.25

Price Performance

Historical Comparison
JAZZ
RNR

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About RNR RenaissanceRe Holdings Ltd.

RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.

Share on Social Networks: